CLDX
Income statement / Annual
Last year (2025), Celldex Therapeutics Inc.'s total revenue was $1.50 M,
a decrease of 78.63% from the previous year.
In 2025, Celldex Therapeutics Inc.'s net income was -$258.80 M.
See Celldex Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.50 M |
$7.02 M |
$6.88 M |
$2.36 M |
$4.65 M |
$7.42 M |
$3.57 M |
$9.54 M |
$12.74 M |
$6.79 M |
| Cost of Revenue |
$0.00
|
$163.55 M
|
$118.01 M
|
$82.26 M
|
$53.31 M
|
$42.53 M
|
$42.67 M
|
$66.45 M
|
$96.17 M
|
$102.03 M
|
| Gross Profit |
$1.50 M
|
-$156.53 M
|
-$111.13 M
|
-$79.90 M
|
-$48.66 M
|
-$35.12 M
|
-$39.10 M
|
-$56.91 M
|
-$83.43 M
|
-$95.24 M
|
| Gross Profit Ratio |
1
|
-22.3
|
-16.15
|
-33.9
|
-10.46
|
-4.73
|
-10.94
|
-5.97
|
-6.55
|
-14.03
|
| Research and Development Expenses |
$245.10 M
|
$163.55 M
|
$118.01 M
|
$82.26 M
|
$56.81 M
|
$40.53 M
|
$42.67 M
|
$66.45 M
|
$96.17 M
|
$102.73 M
|
| General & Administrative Expenses |
$43.80 M
|
$38.55 M
|
$30.91 M
|
$27.20 M
|
$20.49 M
|
$14.46 M
|
$15.43 M
|
$19.27 M
|
$25.00 M
|
$35.98 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$43.80 M
|
$38.55 M
|
$30.91 M
|
$27.20 M
|
$20.49 M
|
$14.46 M
|
$15.43 M
|
$19.27 M
|
$25.00 M
|
$35.98 M
|
| Other Expenses |
$0.00
|
-$163.55 M
|
-$105.51 M
|
-$74.12 M
|
-$54.72 M
|
-$26.75 M
|
-$42.17 M
|
$13.81 M
|
-$83.08 M
|
-$101.03 M
|
| Operating Expenses |
$288.90 M
|
$38.55 M
|
$43.41 M
|
$35.33 M
|
$22.58 M
|
$28.24 M
|
$15.93 M
|
$99.53 M
|
$38.10 M
|
$37.68 M
|
| Cost And Expenses |
$288.90 M
|
$202.10 M
|
$161.43 M
|
$117.59 M
|
$75.89 M
|
$70.77 M
|
$58.60 M
|
$165.97 M
|
$134.27 M
|
$139.70 M
|
| Interest Income |
$28.61 M
|
$37.22 M
|
$13.11 M
|
$2.91 M
|
$505.00 K
|
$2.41 M
|
$4.15 M
|
$4.49 M
|
$4.21 M
|
$4.39 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.38 M
|
$3.18 M
|
$3.01 M
|
$2.90 M
|
$3.07 M
|
$3.93 M
|
$4.86 M
|
$3.80 M
|
$5.31 M
|
$4.09 M
|
| EBITDA |
-$255.42 M |
-$191.90 M |
-$139.03 M |
-$104.20 M |
-$66.08 M |
-$45.64 M |
-$49.67 M |
-$72.60 M |
-$104.02 M |
-$124.44 M |
| EBITDA Ratio |
-170.28
|
-27.34
|
-20.2
|
-44.21
|
-14.21
|
-6.15
|
-13.9
|
-7.61
|
-8.16
|
-18.34
|
| Operating Income Ratio |
-191.6
|
-27.79
|
-22.45
|
-48.89
|
-15.32
|
-8.54
|
-15.4
|
-16.4
|
-9.54
|
-19.59
|
| Total Other Income/Expenses Net |
$28.60 M
|
$37.22 M
|
$13.11 M
|
$2.91 M
|
$505.00 K
|
$2.41 M
|
$4.15 M
|
$4.49 M
|
$4.21 M
|
$4.39 M
|
| Income Before Tax |
-$258.80 M
|
-$157.86 M
|
-$141.43 M
|
-$112.33 M
|
-$70.74 M
|
-$60.95 M
|
-$50.88 M
|
-$151.95 M
|
-$117.31 M
|
-$128.53 M
|
| Income Before Tax Ratio |
-172.53
|
-22.49
|
-20.55
|
-47.66
|
-15.21
|
-8.22
|
-14.24
|
-15.93
|
-9.21
|
-18.94
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$227.00 K
|
-$1.17 M
|
$0.00
|
-$765.00 K
|
-$24.28 M
|
$0.00
|
| Net Income |
-$258.80 M
|
-$157.86 M
|
-$141.43 M
|
-$112.33 M
|
-$70.51 M
|
-$59.78 M
|
-$50.88 M
|
-$151.18 M
|
-$93.03 M
|
-$128.53 M
|
| Net Income Ratio |
-172.53
|
-22.49
|
-20.55
|
-47.66
|
-15.16
|
-8.06
|
-14.24
|
-15.85
|
-7.3
|
-18.94
|
| EPS |
-3.9 |
-2.45 |
-2.92 |
-2.4 |
-1.64 |
-2.02 |
-3.51 |
-14.48 |
-10.86 |
-18.99 |
| EPS Diluted |
-3.9 |
-2.45 |
-2.92 |
-2.4 |
-1.64 |
-2.02 |
-3.51 |
-14.48 |
-10.86 |
-18.99 |
| Weighted Average Shares Out |
$66.50 M
|
$64.40 M
|
$48.45 M
|
$46.89 M
|
$42.87 M
|
$29.64 M
|
$14.51 M
|
$10.44 M
|
$8.57 M
|
$6.77 M
|
| Weighted Average Shares Out Diluted |
$66.50 M
|
$64.40 M
|
$48.45 M
|
$46.89 M
|
$42.87 M
|
$29.64 M
|
$14.51 M
|
$10.44 M
|
$8.57 M
|
$6.77 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
